Canada Viscosupplementation Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Canada Viscosupplementation Market Size - Analysis

The Canada Viscosupplementation Market is estimated to be valued at USD 162.6 Mn in 2025 and is expected to reach USD 275.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032.

Canada Viscosupplementation Market Trends

The growing prevalence of opioid addiction in the United States has contributed significantly to the rise of viscosupplementation procedures in Canada. As the opioid crisis continues to ravage American communities, many individuals suffering from chronic pain and addiction issues are looking north of the border for alternative treatment options.

Canadian clinics near the border have reported substantial increases in American patients in recent years. For example, a clinic in Windsor, Ontario reported a 45% rise in patients from Detroit between 2020-2022.

Market Driver – Increasing Awareness About Opioid Dependence Treatment

As awareness rises on the dangers of prolonged opioid use such as risk of overdose and addiction, more doctors are recommending viscosupplementation for pain management. According to a 2021 report by Health Canada, opioid-related harms continue to rise with over 21,000 deaths attributed to apparent opioid overdoses between January 2016 and September 2021. The burden of prescription opioid addiction on individuals and communities has also increased healthcare costs significantly. Faced with this crisis, the government has been sponsoring educational programs to educate doctors as well as the general public about non-addictive options for chronic pain treatment.

Stringent regulations for prescribing buprenorphine are placing significant restraints on the growth of Canada's viscosupplementation market. Buprenorphine is a critical drug used for pain management, especially for treating osteoarthritis patients undergoing viscosupplementation therapy. However, current regulations in Canada allow only certain certified physicians to prescribe buprenorphine through restricted pathways. This makes the drug inaccessible for a large number of patients undergoing viscosupplementation injections.

The reluctance of arthritis patients to undergo future viscosupplementation cycles further hinders market growth. Medical researchers and insurers also estimate that improving buprenorphine prescribing policies could help increase completion rates for the standard 3-injection viscosupplementation courses by 15-20% (Access to Medicinal Cannabis Act, 2021).

Market Opportunity – Scope for Enhancing Distribution Networks

Widening the scope of distribution networks would allow for easier storage and transportation of products across different climate and terrain zones. This is especially important considering the short shelf life of some viscosupplementation brands. With enhanced cold chain management and monitoring solutions that leverage new technologies, more remote regions that previously faced supply access issues could reliably stock. As the population continues to age over the next decade, the prevalence of osteoarthritis is projected to rise according to Statistics Canada. Improving distribution coverage to reach wider patient populations now would help providers better address future increases in demand for viscosupplementation procedures.

Segmental Analysis of Canada Viscosupplementation Market

Insights, By Dosage: Convenience and Effectiveness Drive Demand For Three-Injection Regimens

Within the Canada viscosupplementation market based on dosage, three-injection sub-segment  command the largest share of 48.1% due to their optimal balance of convenience and clinical effectiveness. Receiving all treatment doses within a single doctor's visit allows providers to fully address patients' pain issues while minimizing disruptions to daily routines from multiple return trips. Both factors are particularly important considerations for the large osteoarthritis patient population facing mobility difficulties.

Notably, the three-injection schedule was pioneered by market leaders whose products have amassed large clinical evidence bases and physician familiarity after decades of use. Trust in the reliability and demonstrated track record of the three-shot regimen prompts many providers and their osteoarthritis patients to opt for this dosage option first. Its stability and ease of administration have also made three injections the clinical standard taught in medical education.

Insights, By Arthritis Type: Osteoarthritis Applications Power Market Growth

Viscosupplementation offers a pharmacologic option for osteoarthritis patients who have found limited pain relief from oral medications or lifestyle changes alone. By potentially blocking enzymes that degrade cartilage and lubricating joints, intra-articular injections of hyaluronic acid derivatives modify the disease process itself rather than just masking symptoms. As a result, durations of effect can last several months—a substantial improvement over oral analgesics.

Competitive overview of Canada Viscosupplementation Market

The major players operating in the canada viscosupplementation market include Anika Therapeutics Inc., Ferring Pharmaceuticals, Bioventus, Mylan N.V., Sanofi S.A., Teva Pharmaceutical Industries Ltd,  Johnson & Johnson., F. Hoffmann-La Roche AG, and Zimmer Biomet.

Canada Viscosupplementation Market Segmentation

• By Dosage
  • Single Injection
  • Three Injection
  • Five Injection
• By Arthritis Type
  • Osteoarthritis
  • Rheumatoid Arthritis
• By End User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others